Clinical Trial Update: A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) [Phase 2]

View source ↗

Summary

A Phase 2 trial by Redx Pharma evaluated RXC004 with or without nivolumab in metastatic, microsatellite-stable colorectal cancer with RNF43 or RSPO aberrations …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• RXC004
• nivolumab (nivolumab)

Snippet

Sponsor: Redx Pharma Ltd | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-04-16